Objective
obese, overweight, T2DM, Diabetes, weight loss
OBESE, DISEASE, TYPE 2 DIABETES MELLITUS, DIABETES
Edited by: Sen Li, Beijing University of Chinese Medicine, ChinaReviewed by: Ping Jin, Third Xiangya Hospital, Central South University, China; Wei Wu, Guangdong Provincial Center for Disease Control and Prevention, China†These authors have contributed equally to this work and share first authorshipThis article was submitted to Clinical Diabetes, a section of the journal Frontiers in EndocrinologyPolyethylene glycol loxenatide (PEG-Loxe) is a novel, once-weekly glucagon-like peptide 1 receptor agonist that is approved in doses of 0.1 mg and 0.2 mg for the treatment of type 2 diabetes mellitus (T2DM). However, no clinical trials have been designed to determine the effect of 0.3 mg PEG-Loxe on weight loss in overweight or obese patients with T2DM. This trial aimed to evaluate the short-term effect of 0.3 mg PEG-Loxe, injected subcutaneously once weekly, for weight management in overweight or obese patients with T2DM.